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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
The primary objective is to examine the effects of behavioural activation compared to any control group for the treatment of depression
in adults with non-communicable diseases (NCDs). The secondary objectives is to examine the effects of behavioural activation compared
to each control group separately (no treatment, waiting list, other psychological therapy, pharmacological treatment, or any other type
of treatment as usual) for the treatment of depression in adults with NCDs.
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B A C K G R O U N D
Description of the condition
Depression
The term 'depression' is often used to describe major depressive
disorder when diagnosed in a clinical setting. It is characterised by
a period of at least two weeks of depressed mood, or a persistent
loss of interest or pleasure in activities which were previously con-
sidered enjoyable, or both (APA 2013). A range of symptoms may
accompany these key features of depression and reduce quality of
life. These include weight loss or weight gain, insomnia or hyper-
somnia, psychomotor agitation or retardation, fatigue, loss of en-
ergy, feelings of excessive guilt and worthlessness, diminished con-
centration, and recurrent thoughts of death (APA 2013).
Depression is the fiJh global cause of disease burden in terms of
years lived with a disability (YLD), and was ranked in the top 10 of
YLD in 191 out of 195 countries worldwide (Vos 2017). In 2014, 7.1%
of the population living in the 28 countries of the European Union
was estimated to report depression, with higher rates reported by
women, older people, and people living in cities (Eurostat 2014).
In a national survey conducted in the USA, the 12-month and life-
time prevalence of depression were 10.4% and 20.6%, respective-
ly (Hasin 2018). Similarly, the lifetime prevalence for depression in
England was 19% in 2014 (HSE 2014). A meta-analysis of data from
35 countries found a 52% increased risk of mortality in people with
depression (Cuijpers 2014). Global estimates of the burden of dis-
ease show that 4.4% of people worldwide suffer from depressive
disorder. These figures vary considerably depending on geograph-
ical regions; for depression, rates vary from 3.6% in the Western Pa-
cific to 5.4% in Africa. More than 80% of people who have mental
disorders live in low- and middle-income countries (Rathod 2017).
Depressive disorders can have a long-lasting impact on patients,
their families, and wider society. They often co-occur with anxi-
ety disorders (WHO 2017), and are associated with marked person-
al and societal economic losses due to healthcare costs for men-
tal and comorbid physical healthcare, reduced productivity in the
workplace, and years of life lost (Alonso 2011; Greenberg 2015).
Non-communicable diseases
Non-communicable diseases (NCDs) are chronic diseases caused
by a combination of genetic physiological, environmental and be-
havioural factors. The four most common physical NCDs are cardio-
vascular disease (CVD), cancer, chronic respiratory diseases, and
type 2 diabetes (WHO 2017). According to the World Health Orga-
nization (WHO), 41 million people die annually due to NCDs, cor-
responding to 71% of all deaths worldwide. NCDs affect people of
all age groups, 15 million occurring between the ages of 30 and 69
years (WHO 2017). Despite the resurgence of certain infectious dis-
eases, such as tuberculosis and dengue, the global burden of infec-
tious disease overall is decreasing (or becoming more stagnant in
some countries), and being replaced by an increased burden of dis-
ease for non-communicable diseases, as well as common mental
disorders (Vos 2017). NCDs decrease patients' health-related qual-
ity of life substantially (Dyer 2010; Solli 2010).
Comorbidity of depressive disorders in patients with non-
communicable diseases
NCDs commonly co-occur with depressive disorders (Patel 2015).
There is a complex bidirectional association between depression
and NCDs (Ngo 2013). Co-existence of depression with a NCD wors-
ens outcomes for both conditions and is associated with poorer
self-management and treatment adherence, reduced treatment re-
sponse and higher morbidity and mortality for both the mental and
the physical disorder (BPS 2010; NICE 2009). NCDs and mental dis-
orders are associated with similar behavioural factors, such as to-
bacco use, unhealthy diet, physical inactivity, and harmful alcohol
use (Stein 2019). Pathophysiological factors, such as increased cy-
tokine levels or other inflammatory markers may increase the risk
of developing and worsening depression (Katon 2003).
CVD is the leading cause of death globally (Roth 2017). Comorbid
depression is common in CVD patients (approximately 15%), and
the prevalence of depression in patients with CVD is higher than
in the general population (Hare 2014). Increased levels of depres-
sion in postmyocardial infarction patients is associated with a 1.6-
to 2.7-fold increased risk of impaired outcomes within 24 months
of the event (Meijer 2011). The association between depression and
CVD risk factors is bidirectional (Pan 2012). Depression is thought
to be a risk factor for CVD through a combination of behavioural
(smoking, alcohol intake, physical inactivity, and obesity) and bio-
logical components (affecting the nervous system, hormone secre-
tion, immune system, and cardiovascular functions) (Dhar 2016).
Prevalence estimates of major depression (15%), minor depres-
sion (20%), and anxiety disorders (10%) in patients treated for can-
cer are more than double that observed in the general population.
Two-thirds of patients with cancer and depression also have clini-
cally significant anxiety symptoms. Figures vary by cancer type and
it is suggested that this is due to the differing prognoses, pain lev-
els, and degrees of body image disruption associated with each tu-
mour type, as well as specific tumour-related neuropsychiatric ef-
fects and treatment-related neuropsychiatric side effects (Pitman
2018).
Mental health problems are approximately three times more preva-
lent among people with chronic obstructive pulmonary disease
(COPD) than in the general population (NICE 2009). Patients with
COPD show increased levels of psychological distress, which in turn
leads to increased exacerbation rates. Up to 55% of patients suf-
fering from COPD also suffer from anxiety and depression (Laurin
2012). In the UK, it was reported that mortality rates for people with
comorbid asthma and depression were twice the level among those
with asthma alone (Walters 2011).
It is estimated that depression occurs in 13% to 18% of diabetic pa-
tients, which worsens glycaemic control and is associated with in-
creased complications. Mild depression is thought to often go un-
diagnosed in diabetic patients because many of the somatic symp-
toms are similar (Hermanns 2013).
Description of the intervention
Pharmacological and psychological interventions, alone or in com-
bination, are recommended in clinical guidelines for the treatment
of mild to moderate depression. Behavioural activation is one of
the recommended therapies (NICE 2009).
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Antidepressants are a standard treatment for moderate to severe
depression in healthcare settings, whereas for subthreshold de-
pressive symptoms or mild depression, low-intensity psychoso-
cial therapy and psychological therapies are recommended (NICE
2009). Although antidepressants have shown efficacy in the treat-
ment of depression, non-adherence to antidepressant medication
is common (Hunot 2007; Ten Doesschate 2009; Van Geffen 2009),
and can lead to relapse and recurrence of depression (Gardarsdot-
tir 2009). Non-adherence is related to a multitude of factors, in-
cluding concerns about antidepressants relating to side effects, de-
pendence, and experience of withdrawal symptoms (Davies 2018;
Hunot 2007; Sansone 2012). Studies of treatment for psychiatric
disorders, including depression, consistently report that patients
prefer psychological treatment to medication (McHugh 2013).
There is a wide range of psychological therapies available for the
treatment of depressive disorders. Psychological therapies may
be categorised into four philosophical and theoretical schools of
thought, comprising psychoanalytic/dynamic (Freud 1949; Jung
1963; Klein 1960), behavioural (Skinner 1953; Watson 1924; Wolpe
1958), humanistic (Maslow 1943; May 1961; Rogers 1951), and
cognitive approaches (Beck 1979; Lazarus 1971). Each school
of thought incorporates several different and overlapping psy-
chotherapeutic approaches.
Behavioural activation stems from a behavioural psychotherapy
approach first developed in the 1970s by Lewisohn and colleagues
(Dimidjian 2011). It is based on the concept that depression re-
sults from deprivation of positive reinforcement, and the treatment
focuses on identifying and scheduling pleasurable activities, thus
increasing contact with sources of positive reinforcement (Kanter
2012).
When cognitive behavioural therapy (CBT) was developed and dis-
seminated, behavioural activation approaches based purely on op-
erant (learning from the consequences of behaviours) and respon-
dent (responsive behaviour as a result of a stimulus) principles
were thought insufficient. However, the interest in the feasibility
of behavioural treatments for depression has since been renewed
(Dimidjian 2011; Ekers 2014; Hopko 2003). Jacobson showed that
the behavioural component of CBT was as effective as the full pack-
age of CBT, and investigators developed a new and more compre-
hensive model of behavioural activation that would be amenable
to dissemination (Jacobson 1996; Jacobson 2001).
How the intervention might work
Skinner proposed that depression was associated with an interrup-
tion in established sequences of healthy behaviour that were pre-
viously positively reinforced by the social environment and were
based on operant conditioning principles (in which behaviour pat-
terns are learnt, rather than instinctive) (Skinner 1953). In subse-
quent expansions of this model, reduction of positively reinforced
healthy behaviours has also been attributed to a decrease in the
number and range of reinforcing stimuli available to the individual,
lack of skill in obtaining positive reinforcement (Lewinsohn 1974),
increased frequency of punishment, or a combination of two or all
of these (Lewinsohn 1984).
Behavioural activation can be defined as a brief psychotherapeutic
approach that seeks to change the way a person interacts with their
environment, aiming to:
1. increase access to positive reinforcers of healthy behaviours;
2. reduce avoidance behaviours that limit access to positive rein-
forcement; and
3. understand and address barriers to activation.
Treatments are collaborative and focused on the present. Many dif-
fering techniques are incorporated into treatment; however all use
self-monitoring of a mood-environment link and scheduling of new
or adaptive behaviours to meet targets (Kanter 2012). In doing so,
the therapy helps people to make contact with potentially reinforc-
ing experiences (Jacobson 2001).
The original model of behavioural activation, developed by Jacob-
son, was defined primarily by the elimination of cognitive interven-
tion elements (Dimidjian 2006). On the basis of its original design,
behavioural activation model components commonly include de-
veloping a shared treatment rationale; increasing access to pleas-
ant events, activities, and consequences; activity scheduling and
developing social skills self-monitoring links between behaviour
and mood; and activity scheduling to promote contact with sources
of positive reinforcement from the person's environment. In some
cases the use of some form of problem solving or functional analy-
sis is added to overcome any potential barriers to the scheduling
of activities. No attempt is made to directly restructure cognitions,
however the exploration of the consequence of rumination in re-
stricting access to positive reinforcement is a common focus of the
approach (Kanter 2012; Veale 2008). The treatment can result in
significant neurobiological changes to the brain's reward circuitry
(Kanter 2012).
It is thought that behavioural activation could be effective in the
treatment of patients with depression and comorbid NCDs by sup-
porting people to identify activities they would like to engage in and
reintroduce valued activities that they have stopped doing. Positive
reinforcement from valued activities through self-monitoring, ac-
tivity scheduling, and functional analysis helps to break the vicious
cycle of limiting activities and depressive symptoms.
Why it is important to do this review
According to the clinical guidelines produced by the National Insti-
tute for Health and Clinical Excellence (NICE), behavioural activa-
tion is one of the recommended treatment options for subthresh-
old depressive symptoms, mild to moderate depression, and se-
vere depression, along with CBT and interpersonal therapy. How-
ever, the guidelines acknowledge that evidence for behavioural ac-
tivation is currently less robust than for the other recommended
therapies (NICE 2009).
Behavioural activation is increasingly receiving attention as a po-
tentially cost-effective intervention for common mental disorders,
including for populations with comorbid NCDs, and it may be easi-
er to deliver and implement than other psychological therapy mod-
els because it can be delivered in less sessions, over a shorter peri-
od of time, and by mental health workers who are not specialists
(Richards 2016). Given this resurgence of interest, a comprehensive
review of the comparative effectiveness and acceptability of behav-
ioural activation interventions for common mental disorders in this
patient group with NCDs is now timely to inform and update clinical
practice and future clinical guideline development.
A Cochrane Review on the effectiveness of behavioural activation
for the treatment of depression is ongoing (Uphoff 2019). To allow
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for meaningful meta-analyses in a relatively homogenous patient
population, people with comorbidities were excluded from that re-
view. The current review will fill this gap in the literature by specifi-
cally addressing the population of people with depression and co-
morbid NCDs.
O B J E C T I V E S
The primary objective is to examine the effects of behavioural ac-
tivation compared to any control group for the treatment of de-
pression in adults with non-communicable diseases (NCDs). The
secondary objectives is to examine the effects of behavioural acti-
vation compared to each control group separately (no treatment,
waiting list, other psychological therapy, pharmacological treat-
ment, or any other type of treatment as usual) for the treatment of
depression in adults with NCDs.
M E T H O D S
Criteria for considering studies for this review
Types of studies
For consistency and to facilitate interpretation of the results of this
review in the wider context of evidence on behavioural activation
for depression, we will follow methods described in the published
protocol 'Behavioural activation therapies for depression in adults'
where possible (Uphoff 2019).
Randomised controlled trials (RCTs) will be eligible for inclusion in
this review. We will include trials employing a cross-over design
(whilst we acknowledge that this design is rarely used in psycho-
logical therapy trials), but we will only use data from the first active
treatment phase. Cluster-RCTs are also eligible for inclusion.
Quasi-RCTs, in which treatment assignment is decided through
methods such as alternate days of the week, are not eligible for in-
clusion.
Types of participants
Participant characteristics
Trials with men and women aged 18 years and over are eligible for
inclusion. We will exclude trials that contain participants under 18
years of age. If a trial includes both adults and children, we will con-
tact authors to request data for adult participants only. If these data
are not available, we will exclude the trial. Participants must have
depression (mild, moderate or severe) with a comorbid non-com-
municable disease (NCD). NCDs to be included are the four most
prevalent NCDs worldwide: cardiovascular disease (CVD), cancer,
chronic respiratory disease and type 2 diabetes. Postnatal depres-
sion is considered a separate condition with contributing factors
distinct from major depressive disorder, and we will therefore ex-
clude patients with this condition. We will also exclude participants
with subthreshold depression.
Setting
Trials could be conducted in a primary, secondary, specialist, or
community setting.
We will exclude trials involving inpatients, as these represent set-
tings which differ with regards to the complexity of patients' health-
care needs, the way patients access care, and the way in which in-
terventions are delivered and embedded in clinical practice. The
same intervention may therefore lead to different results in inpa-
tient settings compared to other settings, and we would not be able
to ascertain whether this would be a result of the type of partici-
pants, the delivery of the intervention, or features of the setting it-
self. If a trial includes both inpatients and outpatient settings, we
will contact authors to request data for participants eligible for in-
clusion in our review only. If these data are not available, we will
exclude the trial.
Nursing homes in this review are considered outpatient settings, as
they are places of residence. Hospice care is considered specialised
medical care and we will therefore exclude studies conducted with
participants in a hospice.
We will include trials that focus on specific populations - nurses,
care givers, participants at a specific workplace with depression - if
all participants meet the criteria for depression.
We will include studies from all countries.
Diagnosis
We will include all trials that focus on acute phase treatment of clin-
ically diagnosed depression in patients with comorbid NCDs (CVD,
cancer, chronic respiratory disease and type 2 diabetes).
We will include trials adopting any standardised diagnostic criteria
to define participants suffering from an acute phase unipolar de-
pressive disorder. Accepted diagnostic criteria include Feighner cri-
teria, Research Diagnostic Criteria and criteria of the Diagnostic and
Statistical Manual of Mental Disorders, Third Edition (DSM-III; APA
1980), DSM-III-Revised (APA 1987),DSM-Fourth Edition (DSM-IV; APA
1994), DSM-IV-Text Revision (APA 2000), DSM-Fi#h Edition (DSM-5;
APA 2013), and International Classification of Diseases, Tenth Edition
(ICD-10; WHO 1992). Earlier trials may have used ICD-Ninth Edition
(ICD-9; WHO 1978), but ICD-9 is not based on operationalised crite-
ria, so we will exclude trials using ICD-9 to diagnose depression.
We include participants diagnosed with anxiety, or with symptoms
of anxiety, as long as they are also diagnosed with depression.
Types of interventions
Experimental interventions
Previously published Cochrane Reviews for treatment of depres-
sion provided a framework for psychological therapies including
behavioural therapy (Churchill 2013; Hunot 2013; Shinohara 2013).
Given recent developments in literature and practice regarding be-
havioural activation approaches, we consider behavioural activa-
tion as part of behavioural therapies, rather than being classified
as a 'third wave' therapy. In line with the behavioural therapy for
depression review (Uphoff 2019), we created the comparator cat-
egories of psychological therapies on the basis of both treatment
approach (e.g. their theoretical background and the manuals used)
and content (e.g. therapeutic techniques employed). See also Ap-
pendix 1.
Behavioural activation
We will include trials evaluating treatment approaches for depres-
sion and anxiety that are either explicitly called 'behavioural acti-
vation', or treatments that are described using the main elements
of behavioural activation for depression, such as pleasant events
and activities, activity scheduling, positive reinforcement from the
Behavioural activation therapies for depression in adults with non-communicable diseases (Protocol)
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environment, positive interaction or re-engagement with the en-
vironment. This means that we will include behavioural therapies
in the treatment group as long as they are described using the
main elements of behavioural activation. Interventions that con-
tain some elements of behavioural therapy, such as cognitive be-
havioural therapy (CBT) or problem solving therapy, are not eligible
for inclusion.
Format of psychological therapies
Therapies delivered by therapists of all levels are eligible for inclu-
sion. This includes psychologists or psychotherapists accredited by
a professional body for psychology or psychotherapy, who com-
pleted formal training to deliver psychological therapies, as well as
lay counsellors and non-specialist therapists who have been specif-
ically trained to deliver treatment according to a behavioural acti-
vation protocol.
We will include computerised and self-help interventions if they
were facilitated by a therapist. This means at least some element of
interaction with a therapist is required.
Psychological therapies conducted on an individual or group basis
are eligible for inclusion.
The number of sessions is not limited, and we accept psychological
therapies delivered in only one session.
Comparators
All comparators are accepted as long as they are not a type of be-
havioural activation. We categorise psychological therapies as be-
havioural therapy, social skills training/assertiveness training, re-
laxation therapy, CBT, third wave CBT, psychodynamic, humanistic
and integrative approaches.
Behavioural therapy
If we identify any behavioural therapies that do not contain the
main elements of behavioural activation, we will include them as
comparators.
Social skills training/assertiveness training
The social skills training model proposes that depressed people
may have difficulty initiating, maintaining and ending conversa-
tions (Jackson 1985). Because of these deficits, the individual is
unable to elicit mutually reinforcing behaviour from other people
in his or her environment. Social skills training subsumes asser-
tion and conversational skills, together with more specialised sub-
skills, such as dating and job interview skills. Different social con-
texts may be targeted, for example interaction with friends, fami-
ly members, people at school, or at work, and interventions such
as instruction, modelling, rehearsal, feedback and reinforcement
are used to enable the development of new responses (Jackson
1985). As assertiveness training represents a key component of so-
cial skills training, we included it in this category.
Relaxation therapy
Relaxation training is a behavioural stress management technique
that induces a relaxation response, helping to switch o the fight/
flight response and causing levels of stress hormones in the blood-
stream to fall. A variety of techniques may be used to induce relax-
ation, the most common of which is Jacobson's progressive muscle
relaxation training (Bernstein 1973).
Cognitive behavioural therapies (CBTs)
In CBT, therapists aim to work collaboratively with patients to un-
derstand the link between thoughts, feelings, and behaviours, and
to identify and modify unhelpful thinking patterns, underlying as-
sumptions and idiosyncratic cognitive schemata about the self,
others and the world (Beck 1979). Cognitive change methods for
depression are targeted at the automatic thought level in the first
instance and include thought catching, reality testing and task as-
signing as well as generating alternative strategies (Williams 1997).
Behavioural experiments are then used to re-evaluate underlying
beliefs and assumptions (Bennett-Levy 2004). We categorised these
therapies into six subcategories: cognitive therapy, rational emo-
tive behaviour therapy, problem solving therapy, self-control ther-
apy, a coping with depression course and other CBTs.
Third wave cognitive and behavioural therapies (third wave CBTs)
Third wave CBT approaches conceptualise cognitive thought
processes as a form of 'private behaviour' (Hayes 2006; Hofmann
2008).  Third wave CBTs target the individual's relationship with
cognitions and emotions, focusing primarily on the function of cog-
nitions, such as thought suppression or experiential avoidance (an
attempt or desire to suppress unwanted internal experiences, such
as emotions, thoughts and bodily sensations (Hofmann 2008). A
range of strategies, including mindfulness exercises, acceptance
of unwanted thoughts and feelings and cognitive diffusion (step-
ping back and seeing thoughts as just thoughts), are used to bring
about change in the thinking process. Drawing from psychody-
namic and humanistic principles, third wave CBT approaches often
place great emphasis on use of the therapeutic relationship. We cat-
egorised these therapies into subcategories: acceptance and com-
mitment therapy, compassionate mind training, functional analyt-
ic psychotherapy, metacognitive therapy, mindfulness-based cog-
nitive therapy, dialectical behaviour therapy and other third wave
CBTs.
Cognitive behavioural therapy bibliotherapy
When the patient does not have access to a qualified therapist or
CBT practitioner they may seek therapy through the use of self-help
materials incorporating a CBT approach (Anderson 2005).
Psychodynamic therapies
Grounded in psychoanalytic theory (Freud 1949), psychodynamic
therapy uses the therapeutic relationship to explore and resolve
unconscious conflict through transference and interpretation, with
development of insight and circumscribed character change as
therapeutic goals, and relief of symptoms as an indirect outcome.
Brief therapy models have been devised by Malan 1963, Mann 1973
and Strupp 1984. Psychodynamic therapies include those based on
a drive/structural model (Freud 1949), relational model (Luborsky
1998; Strupp 1984), and integrative analytic model (Mann 1973),
among others.
Humanistic therapies
Contemporary models of humanistic therapies differ from one an-
other somewhat in clinical approach, but all focus attention on the
therapeutic relationship (Cain 2002), within which therapist 'core
conditions' of empathy, genuineness and unconditional positive
regard (Rogers 1951), are regarded as cornerstones for facilitat-
ing client insight and change. These include the following subcat-
egories: person-centred therapy (Rogerian), gestalt therapy, expe-
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riential therapies, transactional analysis, existential therapy, non-
directive/supportive therapies and other humanistic therapies.
Interpersonal, cognitive analytic and other integrative therapies
Integrative therapies are approaches that combine components of
different psychological therapy models. Integrative therapy mod-
els include interpersonal therapy (Klerman 1984), cognitive analyt-
ic therapy (Ryle 1990), and Hobson's conversational model (Hob-
son 1985), manualised as psychodynamic interpersonal therapy
(Shapiro 1990). With its focus on the interpersonal context, inter-
personal therapy was developed to specify what was thought to
be a set of helpful procedures commonly used in psychotherapy
for depressed outpatients (Weissman 2007), drawing in part from
attachment theory (Bowlby 1980), and CBT within a time-limit-
ed framework. Cognitive analytic therapy, also devised as a time-
limited psychotherapy, integrates components from cognitive and
psychodynamic approaches. The conversational model integrates
psychodynamic, interpersonal and person-centred model compo-
nents.
Counselling interventions traditionally draw from a wide range
of psychological therapy models, including person-centred, psy-
chodynamic and cognitive behavioural approaches, applied inte-
gratively, according to the theoretical orientation of practitioners
(Stiles 2008). Therefore, we will usually include trials of counselling
with integrative therapies. However, if the counselling intervention
consists of a single discrete psychological therapy approach, we
will categorise it as such, even if the intervention is referred to as
'counselling'. If the intervention is manualised, this will inform our
classification.
Motivational interviewing and other forms of integrative therapy
approaches are also included in this category.
Waiting list
Participants are randomly assigned to the active intervention
group or control group, and they will either receive the intervention
first or be assigned to a waiting list until all participants in the in-
tervention group have received the intervention. During the course
of the trial, people on the waiting list can receive any appropriate
medical care.
Attention placebo
We define this as a control condition that is regarded as inactive by
both researchers and participants in a trial.
Psychological placebo
We define this as a control condition in a trial that is regarded by
researchers as inactive but is regarded by participants as active (al-
so called placebo therapy or sham treatment).
Medication
All evidence-based pharmacotherapy, which will predominant-
ly include antidepressants (e.g. selective serotonin reuptake in-
hibitors, serotonin-norepinephrine reuptake inhibitors, mirtazap-
ine, bupropion, nonselective monoamine oxidase inhibitors); any
dose, route of administration, duration, and frequency.
Medical placebo
All types of medical placebos or 'sugar pills'.
No treatment
Trial participants not receiving any treatment for depression during
the course of the trial.
Excluded interventions
We will exclude trials of long-term, continuation or maintenance
therapy interventions designed to prevent relapse of depression
or to treat chronic depressive disorders from this review. Similarly,
we will exclude trials of interventions designed to prevent a future
episode of depression.
We will exclude psychological therapy models based on social con-
structionist principles (that focus on the ways in which individuals
and groups participate in the construction of their perceived social
reality), including couples therapy (Jacobson 1993), family therapy
(Crane 2002), solution-focused therapy (de Shazer 1988), narrative
therapy (White 1990), personal construct therapy (Kelly 1955), neu-
rolinguistic programming (Bandler 1982) and brief problem solving
(Watzlavick 1974). These therapies work with patterns and dynam-
ics of relating within and between family, social and cultural sys-
tems to create a socially constructed framework of ideas (O'Con-
nell 2007), rather than focusing on individuals' reality. A previously
published Cochrane Review on couples therapy for depression has
recently been updated (Barbato 2018), and a review of family ther-
apy for depression is to be updated (Henken 2007).
Types of outcome measures
Primary outcomes
1. Treatment efficacy for depression: the number of participants
who responded to treatment, as determined by changes in
scores for Beck Depression Inventory (BDI; Beck 1961), Hamil-
ton Rating Scale for Depression (HAM-D/HDRS; Hamilton 1960),
or Montgomery-Asberg Depression Rating Scale (MADRS; Mont-
gomery 1979), or in scores from any other validated depression
scale. We will use HAM-D, and if this is not available we will
use MADRS, and if the latter is not available then we will use
BDI. If BDI is not available we will use the measure most fre-
quently used across trials. Many trials define response as 50%
or greater reduction on BDI, HAM-D, etc., with some trials defin-
ing response using Jacobson's Reliable Change Index (Jacobson
1992); we accepted the trial authors' original definition and pre-
ferred Jacobson's Reliable Change Index if this was used in ad-
dition to other response outcomes.
2. Treatment acceptability: the number of participants who
dropped out of psychological therapy for any reason at all re-
ported time points.
Secondary outcomes
1. Improvement in depression symptoms, based on a continuous
outcome of group mean scores at the end of treatment. If multi-
ple measures have been used for this outcome within one trial,
we will adopt the same hierarchy used for the primary outcome
'treatment efficacy for depression'.
2. Quality of life, as assessed with the use of validated measures
such as Short Form (SF)-36 (Ware 1993), EQ-5D (EuroQol; Brooks
1995), and World Health Organization Quality of Life (WHOQOL;
WHOQL 1998).
3. Social adjustment and social functioning, including Global As-
sessment of Function scores (Luborsky 1962).
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4. Improvement in anxiety symptoms, as measured using a val-
idated continuous scale, either assessor-rated, such as the
Hamilton Anxiety Scale (HAM-A; Hamilton 1959), or self-report,
including the Trait subscale of the Spielberger State-Trait Anxi-
ety Inventory (STAI-T; Spielberger 1983), and the Beck Anxiety
Inventory (BAI; Beck 1988). We will use HAM-A, and if this is not
available we will use STAI-T, and if this is not available we will
use BAI. If BAI is not available we will use the measure most fre-
quently used across trials.
5. We will collect any data on adverse effects, such as counts of
completed suicides, attempted suicides, or worsening of symp-
toms for each study and summarise the data in narrative form. 
Search methods for identification of studies
Electronic searches
An Information Specialist will conduct searches on the follow-
ing bibliographic databases using relevant subject headings (con-
trolled vocabularies) and search syntax, appropriate to each re-
source. The search strategies will be designed to identify RCTs of
'behavioural activation', or the main elements of behavioural acti-
vation in participants with the four most common physical NCDs
(cardiovascular disease (CVD), cancer, chronic respiratory diseases,
and type 2 diabetes) who have also been clinically diagnosed with
a depressive disorder. We will search the databases below, includ-
ing global health databases to capture emerging evidence on the
effectiveness of behavioural activation in populations with comor-
bidities in low- and middle-income countries.
1. Cochrane Common Mental Disorders Trials Register (CCMD-
CTR), all available years.
2. Cochrane Central Register of Controlled Trials (CENTRAL; cur-
rent issue).
3. Ovid MEDLINE (1946 onwards) (Appendix 2).
4. Ovid Embase (1980 onwards).
5. Ovid PsycINFO (1806 onwards).
6. Ovid Global Health.
7. Latin American and Caribbean Health Sciences Literature
(LILACs), all available years (via WHO Global Health Index
Medicus).
8. African Index Medicus, all available years (via WHO Global Health
Index Medicus).
9. Index Medicus for the South East Asia Region (ISMEAR), all avail-
able years (via WHO Global Health Index Medicus).
We will not apply any restrictions on date, language or publication
status to the searches.
We will search international trials registries via the World Health Or-
ganization's trials portal (ICTRP), and ClinicalTrials.gov to identify
unpublished or ongoing trials.
We will rerun all searches close to publication if the initial search
date is greater than 12 months. We will also search for any relevant
retraction statements and errata.
Searching other resources
Grey literature
We will search the following sources of grey literature (primarily for
dissertations and theses).
1. Open Grey (www.opengrey.eu).
2. ProQuest Dissertations & Theses Global (www.pro-
quest.com/products-services/pqdtglobal.html).
3. DART-Europe E-theses Portal (www.dart-europe.eu).
4. EThOS - the British Libraries e-theses online service
(ethos.bl.uk).
5. Open Access Theses and Dissertations (oatd.org).
Reference lists
We will check the reference lists of all included trials and relevant
systematic reviews to identify additional trials missed from the
original electronic searches (e.g. unpublished or in-press citations).
Personal communication
We will contact trial authors and subject experts for information on
unpublished or ongoing trials, or to request additional trial data.
Data collection and analysis
Selection of studies
At least two review authors (EU, MPi) will examine the abstracts of
all publications obtained through the search strategy. We will then
obtain full articles of all trials identified by any one of the review au-
thors and two review authors (EU, MPi, DB, PM, MPu, RR) will inde-
pendently assess full-texts according to the criteria relating to char-
acteristics of the studies, participants, and interventions. We will
discuss reasons for disagreement with a third review author (EU,
RC, NS, or DE) and contact external experts or trial authors if neces-
sary in order to reach agreement. We will record reasons for exclud-
ing records at this stage. For all included studies, we will link mul-
tiple reports from the same study. We will present a PRISMA flow
diagram to show the process of study selection (Moher 2009).
Data extraction and management
At least two review authors (EU, DB, PM, MPu, RR) will independent-
ly extract data from each trial. These review authors will discuss any
disagreement with an additional review author (EU, RC, NS, or DE),
and, when necessary, will contact the authors of the trials for fur-
ther information.
We will extract and enter into a spreadsheet information regard-
ing the following: trial population, sample size, interventions, com-
parators, potential biases in the conduct of the trial, source of fund-
ing, outcomes (including adverse events, number needed to treat
for an additional beneficial outcome (NNTB)), follow-up and meth-
ods of statistical analysis.
Management of time points
We plan to summarise and categorise post-treatment outcomes
and outcomes at each reported follow-up point as follows: short-
term (up to 6 months post-treatment), medium-term (7 to 12
months post-treatment) and long-term (longer than 12 months).
Assessment of risk of bias in included studies
We will assess risk of bias for each included trial using the Cochrane
'Risk of bias' tool (Higgins 2016), which considers the following do-
mains.
1. Risk of bias arising from the randomisation process, including
allocation and randomisation.
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2. Risk of bias due to deviations from the intended interventions,
including blinding of participants and people delivering the in-
terventions.
3. Missing outcome data.
4. Risk of bias in measurement of the outcome, including blinding
of outcome assessors.
5. Selective outcome reporting.
6. Other sources of bias.
For cluster-RCTs and cross-over trials, we will use the templates
specifically designed to assess these types of trials, with the same
domains.
In the 'Other sources of bias' domain we will consider any addition-
al problems with bias, including the following issues specific to psy-
chological therapy trials.
1. Treatment fidelity: was the therapy monitored against a manual
or a scale through audiotapes or videotapes?
2. Researcher allegiance/conflict of interest: did the researcher
have a vested interest for or against the therapies under exami-
nation?
3. Therapist allegiance/conflict of interest: did the therapist have
a vested interest for or against the therapies provided?
We will make a judgement on the risk of bias for each domain within
and across trials, and categorise this as low, unclear, or high risk of
bias.
Two review authors (EU, DB, PM, MPu, RR) will independently as-
sess the risk of bias in selected trials and discuss any disagreements
with a third review author (EU, RC, NS, or DE). Where necessary, we
will contact trial authors for further information. We will present all
'Risk of bias' data graphically, and narratively in the text. We will
use allocation concealment as a marker of trial quality for the pur-
pose of undertaking sensitivity analyses.
Measures of treatment e:ect
Continuous outcomes
Where trials use the same outcome measure for comparison, we
will pool data by calculating the mean difference (MD). When trials
use different measures to assess the same outcome, we will pool
data with standardised mean difference (SMD) and calculate 95%
confidence intervals (CIs).
A SMD of zero means that the intervention and control groups have
equivalent treatment effects. We anticipate that, for most mea-
sures, a lower score will indicate greater improvement. For exam-
ple, a lower score on depression symptom instruments indicates an
improvement in symptoms. In these cases, a SMD less than zero in-
dicates that the intervention has a greater effect than the control. A
SMD greater than zero indicates that the intervention has a small-
er effect than the control. Interpretation of the SMD is reversed in
cases where a greater continuous score indicates greater improve-
ment.
Dichotomous outcomes
We will analyse dichotomous outcomes by calculating a pooled risk
ratio (RR) and 95% CIs for each comparison.
In addition, we will calculate the number needed to treat to bene-
fit (NNTB) with 95% CIs for all dichotomous outcomes to facilitate
interpretation; this is the expected number of people who need to
receive the intervention rather than the comparator for one addi-
tional person to achieve a beneficial outcome (Schünemann 2017).
If one trial uses both continuous and dichotomous variables for the
same outcome, we will give preference to the continuous outcome.
If different outcomes are used, for example depression score and
clinical depression yes/no, we will report both.
Unit of analysis issues
Cluster-randomised trials
We will include cluster-randomised trials as long as proper adjust-
ment for the intracluster correlation can be conducted in accor-
dance with the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Higgins 2011a).
Cross-over trials
We will include trials employing a cross-over design in the review,
but we will only use data from the first active treatment phase.
Trials with multiple treatment groups
Multiple-arm trials (those with more than 2 intervention arms) can
pose analytical problems in pair-wise meta-analysis. For trials with
more than two relevant active treatment arms, we will manage da-
ta in this review as follows.
Dichotomous data
We will collapse data from relevant active intervention arms into
a single arm for comparison, or we will split data from relevant ac-
tive intervention arms equally between comparator arms (Higgins
2011b).
Dealing with missing data
We will manage missing dichotomous data through intention-to-
treat (ITT) analysis, in which we will assume that participants who
dropped out after randomisation had a negative outcome. We al-
so plan to conduct best/worse case scenarios for the clinical re-
sponse outcome, in which we will assume that dropouts in the ac-
tive treatment group had positive outcomes and those in the con-
trol group had negative outcomes (best case scenario), and that
dropouts in the active treatment group had negative outcomes and
those in the control group had positive outcomes (worst case sce-
nario), thus providing boundaries for the observed treatment ef-
fect. If a large amount of information is missing, we will give these
best/worst case scenarios greater emphasis in the presentation of
results.
We will analyse missing continuous data on an endpoint basis, in-
cluding only participants with a final assessment, or by using the
last observation carried forward (LOCF) to the final assessment, if
trial authors report LOCF data. When SDs are missing, we will at-
tempt to obtain these data by contacting trial authors. When SDs
are not available from trial authors, we will calculate them from P
values, t-values, CIs or standard errors, if these are reported in the
articles (Deeks 1997).
If a vast majority of SDs are available and only a minority of SDs are
unavailable or unobtainable, we plan to use the method devised by
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Furukawa and colleagues to impute SDs and calculate percentage
responders (da Costa 2012; Furukawa 2005; Furukawa 2006). If we
use this method, we will interpret data with caution and will take
into account the degree of observed heterogeneity. We will also un-
dertake a sensitivity analysis to examine the effect of the decision
to use imputed data.
If additional figures are not available or obtainable and it is not
deemed appropriate to use the Furukawa method as described
above, we will not include the trial data in the comparison of inter-
est.
Assessment of heterogeneity
We will assess statistical heterogeneity using the Chi2 test, which
provides evidence of variation in effect estimates beyond that of
chance. Because the Chi2 test has low power to assess heterogene-
ity when a small number of participants or trials are included, we
will conservatively set the P value at 0.1 (Deeks 2017). We will al-
so quantify heterogeneity using the I2 statistic, which calculates
the percentage of variability due to heterogeneity rather than to
chance (Higgins 2003). We consider I2 statistic values in the range of
50% to 90% to represent substantial statistical heterogeneity and
will explore them further. However, the importance of the observed
I2 statistic depends on the magnitude and direction of treatment
effects and the strength of evidence for heterogeneity. Forest plots
generated in Review Manager 5 (RevMan 5; Review Manager 2014),
will provide an estimate of tau2, the between-trial variance in a ran-
dom-effects meta-analysis (Deeks 2017). To provide an indication
of the spread of true intervention effects, we will also use the tau2
estimate to determine an approximate range of intervention effects
for the primary outcome using the method outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Deeks 2017).
Assessment of reporting biases
As far as possible, we will minimise the impact of reporting bias-
es by undertaking comprehensive searches of multiple sources (in-
cluding trials registries), to identify unpublished material and in-
cluding non–English language publications.
We will also try to identify outcome reporting bias in trials by
recording all trial outcomes, planned and reported, and noting
where outcomes are missing. If we find evidence of missing out-
comes, we will attempt to obtain any available data directly from
the trial authors.
We plan to construct funnel plots to establish the potential influ-
ence of reporting biases and small-trial effects (Sterne 2017).
Data synthesis
We plan to conduct a meta-analysis of included trials. Given the po-
tential heterogeneity of behavioural activation approaches for in-
clusion, together with the likelihood of differing secondary comor-
bid mental disorders and different NCDs in the population of inter-
est, we will use a random-effects model in all analyses.
Subgroup analysis and investigation of heterogeneity
Clinical heterogeneity
We plan to conduct the following subgroup analyses for primary
outcomes treatment efficacy and treatment acceptability, for the
main comparison 'behavioural activation versus any control group'.
1. Country: we plan to conduct subgroup analyses with studies
conducted in high-income countries and studies conducted in
low- and middle-income countries, as we expect the study set-
ting to influence heterogeneity. Countries are grouped accord-
ing to the World Bank income classification (The World Bank
2019).
2. Level of therapist: we plan to conduct analyses separately for
specialist (qualified or accredited mental health specialist with
substantial training), non-specialist (short training, lay workers
or primary care workers) therapists, or specialist in training (e.g.
several years of training in psychotherapy or mental health nurs-
ing). Although psychotherapy has traditionally been delivered
by mental health specialists, the effectiveness of behavioural ac-
tivation delivered by non-specialists is of great interest in low-
resource settings such as low- and middle-income countries.
3. Type of NCD: we plan to analyse data for subgroups: CVD, can-
cer, chronic respiratory disease and type 2 diabetes because we
expect that these different NCDs might affect mental health dif-
ferently, and factors associated with these diseases might influ-
ence success of behavioural activation therapy.
Sensitivity analysis
We plan to conduct the following sensitivity analyses for primary
outcomes treatment efficacy and treatment acceptability, for the
main comparison 'behavioural activation versus any control group'.
1. Trial quality: we will exclude low quality trials in a sensitivity
analysis, if we identify a number of higher quality trials. As a
marker of quality, we will use the 'allocation concealment' cri-
teria from the 'Risk of bias' assessment.
2. Mode of delivery: we will exclude therapies delivered through
computer-based or electronic guidance without a substantial
face-to-face component.
3. Group therapy: we will exclude trials of group therapy for behav-
ioural activation as the mode of delivery of psychotherapy could
influence effectiveness of the therapy.
'Summary of findings' table
We plan to construct a 'Summary of findings' table to present the
main findings of the review. We will report the outcomes listed be-
low and present standardised effect size estimates and 95% CIs.
Two review authors (EU, MPi, DB, RR, PM, MPu, RR) will indepen-
dently use the GRADE approach to assess the quality of the evi-
dence for each outcome, and agreement will be sought between
them, if necessary with help from a third review author (EU, RC,
NS, DE) (Schünemann 2017). We will use GRADEproGDT to create
our 'Summary of findings' table (GRADEpro), and follow standard
methods as described in the Cochrane Handbook for Systematic Re-
views of Interventions to prepare our 'Summary of findings' table
(Schünemann 2011).
In line with our first objective, the comparison included in the 'Sum-
mary of findings' table will be behavioural activation versus any
control group.
We will include the following outcomes (measured up to 24
months) in the 'Summary of findings' table.
1. Treatment efficacy (number of participants responding to treat-
ment).
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2. Treatment acceptability (number of participants who dropped
out).
3. Improvement in depression outcomes as a continuous score.
4. Quality of life.
5. Social adjustment/functioning score.
6. Improvement in anxiety symptoms as a continuous score.
We will create the 'Summary of findings' table before writing our
discussion, abstract, and conclusions, so that the review authors
can jointly consider the potential impact of the study quality for
each outcome on the mean treatment effect and our confidence in
these findings. Our confidence in the mean treatment effects based
on the GRADE assessments will then be reflected in the interpreta-
tion of the results, which informs the abstract, lay summary, and
discussion sections of the review.
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A P P E N D I C E S
Appendix 1. Categories of psychological therapies
 
Categories Abbrevia-
tion
Subcategories Abbrevia-
tion
Behavioural therapy (Lewinsohn)  
Behavioural activation (original model) (Jacobson) BA
Social skills training/assertiveness training SST/asser-
tion
Relaxation therapy  
1. Behavioural ther-
apies
BT
Other behavioural therapies  
Cognitive therapy  
Rational emotive behaviour therapy  
Problem solving therapy  
Self-control therapy  
Coping with depression course  
2. Cognitive-behav-
ioural therapies
CBT
Other cognitive behavioural therapies  
Acceptance and commitment therapy ACT3. Mindful-
ness-based 'third
wave' cognitive and
Third wave
CBT
Compassionate mind training  
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Functional analytic psychotherapy  
Extended behavioural activation eBA
Metacognitive therapy  
Mindfulness-based cognitive therapy  
Dialectical behaviour therapy  
behavioural thera-
pies
Other third wave cognitive and behavioural therapies
(other third wave CBT)
 
Drive/structural model (Freud)  
Relational model (Strupp, Luborsky)  
Integrative analytic model (Mann)  
4. Psychodynamic
therapies
 
Other psychodynamic therapies  
Person-centred therapy (Rogerian)  
Gestalt therapy  
Experiential therapies  
Transactional analysis  
Existential therapy  
Non-directive/supportive therapies  
5. Humanistic ther-
apies
 
Other humanistic therapies  
Interpersonal therapy IPT
Cognitive analytic therapy CAT
Psychodynamic interpersonal therapy  
Cognitive behavioural analysis system of psychotherapy  
Counselling  
Motivational interviewing  
6. Interpersonal,
cognitive analytic
and other integra-
tive therapies
 
Other integrative therapy approaches  
  (Continued)
 
Appendix 2. MEDLINE search strategy
Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily <1946 onwards>
1 ((behavio* adj1 activat*) or BATD).tw,kf.
2 behavio*.mp. and (self adj (evaluat* or monitor*)).tw,kf.
3 (behavio* adj2 (contracting or modification or modify*)).tw,kf.
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4 reinforc*.ti,kf.
5 (reinforce or reinforcer or reinforcement or reinforcements or re-inforcement or re-inforcements).ab. /freq=2
6 (reinforc* adj3 (behavio* or environment* or experience*)).tw,kf.
7 (reinforc* adj1 (positive or contingent)).tw,kf.
8 (activit* adj2 schedul*).tw,kf.
9 ((pleas* or enjoy* or reward*) adj4 (activit* or event?)).tw,kf.
10 ((operant or instrumental) adj (conditioning or learning)).tw,kf.
11 (positive interaction* or avoida* coping or environmental contingenc* or contingency management).tw,kf.
12 functional analysis.tw,kf.
13 ((gain? or reapprais*) adj2 focus*).tw,kf.
14 ((psychoeducat* or psycho-educat*) and (behavi* or coping or self manag*)).ti,ab,kf.
15 or/1-14 [Behavioural Activation]
16 Depression/
17 exp depressive disorder/
18 (depressi* or depressed).tw,kf.
19 dysthymi*.tw,kf.
20 distress*.tw,kf.
21 (mood? or mental health or ((emotion* or psychological) adj trauma*)).tw,kf.
22 "common mental disorder*".tw,kf.
23 or/16-22 [Depression - Cochrane terms]
24 15 and 23 [BA and Depression]
25 Behavior Therapy/
26 (behavio* adj (counsel* or intervention or train* or treatment or therapy or psychotherapy)).tw,kf.
27 25 or 26 [Behaviour therapy]
28 23 and 27 [Behaviour Therapy and Depression]
29 24 or 28 [BA or Behaviour Therapy AND Depression]
30 Pulmonary disease, chronic obstructive/
31 Bronchitis, chronic/ or Pulmonary emphysema/
32 Lung diseases, obstructive/
33 exp Asthma/
34 exp Respiratory Hypersensitivity/
35 Hypertension, Pulmonary/
36 asthma*.tw,kf.
37 ((long-term or longterm or chronic*) adj5 (bronchitis or respirat*)).tw,kf.
38 emphysema*.tw,kf.
39 (obstruct* adj3 (pulmonary or lung* or airway* or airflow* or bronch* or respirat*)).tw,kf.
40 ((hyper responsiveness or hyper-responsiveness or allergy or allergi* or hypersensitiv*) adj5 (airway? or respirat*)).tw,kf.
41 ((long-term or longterm or Chronic* or occupational) adj2 lung* adj5 (condition* or disease* or symptom* or problem* or failure*)).tw,kf.
42 (respirat* adj2 (condition* or disease* or symptom* or problem*)).tw,kf.
43 pulmonary hypertension.tw,kf.
44 (COPD or COAD or COBD or AECB).tw,kf.
45 or/30-44 [Chronic Respiratory Diseases]
46 exp Diabetes mellitus/
47 Glucose Tolerance Test/
48 Glycated Hemoglobin A/
49 diabet*.tw,kf. (601034)
50 (noninsulin*-depend* or non-insulin*-depend* or noninsulin*depend* or non-insulin*depend*).tw,kf.
51 (fasting glucose or plasma glucose or glucose tolerance test* or (glyc?emic adj2 control*)).tw,kf.
52 (HbA1c or A1C or A1c or Hb1c or ((glycated or glycosylated) adj h?emoglobin?)).tw,kf. (50626)
53 (NIDDM or T2D or T2DM).tw,kf.
54 or/46-53
55 exp Diabetes Insipidus/
56 diabet* insipidus.tw,kf.
57 55 or 56
58 54 not 57 [Diabetes]
59 exp Cardiovascular Diseases/
60 (cardio* or cardia* or CVD).tw,kf.
61 (heart* or coronary*).tw,kf.
62 (angina* or ventric*).tw,kf.
63 (myocard* or pericard*).tw,kf.
64 (isch?em* or cerebrovasc*).tw,kf.
65 exp Stroke/
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66 (stroke or strokes or poststroke).tw,kf.
67 apoplexy.tw,kf.
68 (brain adj2 accident*).tw,kf.
69 ((brain* or cerebral or lacunar) adj2 infarct*).tw,kf.
70 exp Hypertension/
71 (hypertensi* or hyperlip*).tw,kf.
72 (hypercholester* or hypertriglycerid*).tw,kf.
73 exp Arteriosclerosis/
74 exp Cholesterol/
75 (cholesterol or arteriosclero* or atherosclero* or peripheral arter* disease*).tw,kf.
76 Blood Pressure/
77 blood pressure.tw,kf.
78 (emboli* or arrhythmi*).tw,kf.
79 (thrombo* or "atrial fibrillat*").tw,kf.
80 (tachycardi* or endocardi* or "sick sinus").tw,kf.
81 or/59-80 [CVD]
82 exp Neoplasms/
83 (cancer* or neoplas* or tumo* or carcinoma* or hodgkin* or nonhodgkin* or adenocarcinoma* or leuk?emia* or metasta* or malignan*
or lymphoma* or sarcoma* or melanoma* or myeloma* or oncolog* or psychoongology or psycho-oncology).tw,kf.
84 82 or 83 [Cancer]
85 45 or 58 or 81 or 84 [COPD Diabetes CVD or Cancer]
86 randomized controlled trial.pt.
87 controlled clinical trial.pt.
88 randomized.ab.
89 placebo.ab.
90 clinical trials as topic.sh.
91 randomly.ab.
92 trial.ti.
93 86 or 87 or 88 or 89 or 90 or 91 or 92
94 exp animals/ not humans.sh.
95 93 not 94
96 29 and 85 and 95 [BA or Behaviour therapy and CMDs and COPD Diabetes CVD Cancer and RCTs]
97 29 and 85
98 limit 97 to "systematic review"
99 96 or 98 [BA or Behaviour Therapy and CMDs and COPD Diabetes CVD Cancer and RCTs OR systematic reviews]
100 (exp Child/ or Adolescent/ or exp Infant/) not exp Adult/
101 99 not 100
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